METHODS: From March 2016 to March 2017, 90 cases of patients with non-proliferative diabetic retinopathy were studied. According to the simple random method were divided into control group(routine treatment to diabetic retinopathy), routine dose group(conventional treatment to diabetic retinopathy + Ligustrazine 120mg), high dose group(conventional treatment to diabetic retinopathy+Ligustrazine 240mg). The changes of hemodynamics, therapeutic effect and adverse reaction were compared among the three groups.

RESULTS: The peak systolic blood flow velocity(PSV)and end diastolic blood flow velocity(EDV)of central retinal artery, posterior ciliary artery and ophthalmic artery in three groups after treatment were higher than those before treatment, and the resistance index(RI)was lower than that before treatment(P<0.05); the PSV and EDV of central retinal artery, posterior ciliary artery and ophthalmic artery in the conventional dose group and the high dose group after treatment were higher than those in the control group, and RI was lower. There was no significant difference in PSV, EDV and RI of central retinal artery, posterior ciliary artery and ophthalmic artery between routine dose group and high dose group(P>0.05). The effective rates of control group, routine dose group and high dose group were 40%, 70% and 77%, respectively. There was significant difference between the two groups(P<0.017). The incidence of adverse reactions in control group, conventional dose group and high dose group were 17%, 23% and 27%, respectively, with no significant difference(P>0.05).

CONCLUSION: In the treatment of non-proliferative DR, the combination of Ligustrazine on the basis of routine treatment can improve the therapeutic effect, improve local blood circulation, and increase the use of Ligustrazine can improve the therapeutic effect, without increasing the risk of adverse reactions. Therefore, 240mg Ligustrazine is recommended for the treatment of DR.